Flagship Biosciences
Flagship Biosciences is recorded as a service provider in 20 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 20 trials · Latest update first
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)
Sponsor Entrada Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Sponsor Entrada Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
Sponsor Acerta Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor Kartos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy
Sponsor Solid Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Sponsor Kartos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)
Sponsor Entrada Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Sponsor Dyne Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Sponsor Tango Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Sponsor Leap Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Sponsor Kartos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
Sponsor Leap Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy with Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma
Sponsor Telios Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Sponsor Sellas Life Sciences Group Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Flagship Biosciences?
The 2026-10-09 snapshot links Flagship Biosciences to 20 distinct CTIS trials. Recorded services include Laboratory services, Biomarker analysis, Genetic testing, Specialty lab - sample testing for tumor DKK1 levels & PD-L1, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Flagship Biosciences?
The most frequently recorded therapeutic areas are Haematological Malignancies, Genetic and Congenital Disorders, Musculoskeletal, Neurology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Flagship Biosciences conducted?
The linked trials record locations in 21 countries, including Italy, Spain, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Flagship Biosciences delivered services.
What can this page tell me about Flagship Biosciences's trial experience?
Browse 20 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Flagship Biosciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Flagship Biosciences Inc.